Arkadiusz Z. Dudek, MD, medical oncologist at Regions Hospital Care Center in St. Paul, Minnesota, discusses a phase 2 trial of nivolumab plus ramucirumab in previously treated mesothelioma patients. This treatment regimen appears well tolerated, with few immune-related toxicities. Dr. Dudek notes that infusion time is short, requiring approximately 3 hours of total clinic time.